Allovir Inc is a biotechnology company focused on developing innovative cell therapies aimed at treating viral infections in immunocompromised patients
The company leverages its proprietary technology platform to produce potential therapies that can enhance the immune response against viral pathogens, particularly in individuals with weakened immune systems, such as those undergoing stem cell transplants or other forms of immunosuppression. By harnessing the power of T-cells, Allovir aims to provide effective treatment options for viral infections that currently have limited therapeutic alternatives, ultimately improving patient outcomes and quality of life.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also rose, gaining, 0.15% to 4,753.64.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500 also rose, gaining, 0.28% to 4,759.82.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose 0.30% to 15,008.08. The S&P 500 also rose, gaining, 0.31% to 4,761.25.
AlloVir Inc (NASDAQALVR) provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-
U.S. stocks traded mixed, with the Dow Jones falling around 150 points on Monday. Here are some big stocks recording gains in today’s session. Genelux Corporation (NASDAQGNLX) gained 19.2% to $28.58. The company recently recently posted second-quarter results.
